Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
about
Molecular pathology in epidemiologic studies: a primer on key considerationsFactors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysisBarriers to preventive therapy for breast and other major cancers and strategies to improve uptakeCombination of Antiestrogens and Omega-3 Fatty Acids for Breast Cancer PreventionCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyExemestane for breast cancer prevention: a critical shift?Potential Mechanisms underlying the Protective Effect of Pregnancy against Breast Cancer: A Focus on the IGF PathwayCancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approachesClinical utilities of aromatase inhibitors in breast cancerCurrent strategies for the prevention of breast cancerOral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug.How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.SI RLTD: Risk Scores and Decision Making: The Anatomy of a Decision to Reduce Breast Cancer Risk.The manner in which calories are restricted impacts mammary tumor cancer preventionWomen's preferences for selective estrogen reuptake modulators: an investigation using the time trade-off technique.An Effective Multimodal Curriculum to Teach Internal Medicine Residents Evidence-Based Breast Health.Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillanceHormone Replacement Therapy, Likely Neither Angel Nor Demon.Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.Awareness of preventive medication among women at high risk for breast cancer and their willingness to consider transdermal or oral tamoxifen: a focus group study.Acceptance and adherence to chemoprevention among women at increased risk of breast cancerEstimating the risks and benefits of tamoxifen for prophylactic breast cancer chemoprevention in Korea.My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR).Tamoxifen augments the innate immune function of neutrophils through modulation of intracellular ceramide.Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.Premenopausal serum androgens and breast cancer risk: a nested case-control study.Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populAffective forecasting and medication decision making in breast-cancer preventionQuality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancerUptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer.Establishing a program for individuals at high risk for breast cancer.Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction.Benign breast disease, mammographic breast density, and the risk of breast cancer.Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.Tamoxifen vs Raloxifene vs Exemestane for ChemopreventionUse of tamoxifen and raloxifene for breast cancer chemoprevention in 2010Effects of tomato- and soy-rich diets on the IGF-I hormonal network: a crossover study of postmenopausal women at high risk for breast cancer.Prevalence of chemopreventive agent use among hospitalised women at high risk for breast cancer: a cross-sectional study.Development of a personalized decision aid for breast cancer risk reduction and management.
P2860
Q24598972-C5F5DA1C-56EF-4CB0-A8A3-5314711A028EQ26773464-C374B375-0E90-43C8-B1C3-0BDA84E4C2CEQ26774593-D0DD16A9-D809-4559-9226-E4DF56F04587Q26784486-8A157C31-ECA5-4BF1-A618-1DB319D50CADQ27011658-CAACEB67-461F-40F9-A98F-22A192C6604CQ27028211-2561F0F3-CC5E-40C4-9FFA-070DABADE879Q28069539-7BE22BB2-8541-4994-8455-E5CAFFC1BD37Q28080472-6FA4E2D1-E257-4433-AD4C-6FF3D7AAD76FQ28081168-4CA80181-4685-452F-8EE4-A70E4C639359Q33599463-AA580731-D03F-49FD-BDE5-29B3C3247EA1Q33739214-BCC2FD0E-DD4D-4263-BD01-0E276C292AE9Q33767120-3F4A7C63-13DB-4910-A53C-98B769DD095DQ33901385-97B57F46-4AD7-4EC7-B772-C4888916EB53Q35072487-74D8600B-DADC-4FF7-8CB7-CD72A22EA525Q35306366-19156BD5-F710-486E-A153-E3185DF43EF5Q35661551-74C28C51-7A80-443E-92C5-DD6655E9D0E5Q35770373-C7CE2CED-8D3C-421E-9BDE-632090B634BEQ35777905-F5A648B5-9B9F-4BF4-9EE3-60C856CF7175Q35780539-C2D246A2-6342-4EBF-86A0-536EE2FD9E5BQ35812120-F54804C2-4C0A-44C5-AF64-7CBD9EFB05A4Q35836307-B1A90AC6-0A03-4E88-B5F8-6A7DF6C40019Q35854935-B1713CEF-E236-4719-8B24-79C4E8459196Q35866934-B5ED80D5-316F-448D-AE8D-EDAD81729DABQ36117814-DA583901-EB12-473A-97F9-521F7772AEB1Q36174776-06F175F2-00F8-46EC-88A2-8916126A15A0Q36363405-BED22C94-E5B7-418C-8524-14F0047E80B5Q36393224-BE7C4736-D19A-45FA-BA7F-A6614FB62980Q36647007-A992D4AF-D940-49F3-BB88-6C8B7F2135CFQ36905513-33DA35F7-7444-44B8-8456-0314AF124F46Q36934323-B991524C-8B20-46BD-B839-6E927B580CBDQ36947842-8DF55027-7DEC-4465-9C92-E0E79CC0D65DQ36983389-225A7FC1-A214-478A-A70C-D4988363D2E5Q37017096-84979966-5CFE-427B-9D70-9406AB17D75FQ37021220-7213BE01-03C6-4E9A-A406-7CF26257CDDBQ37091358-A5D2C910-4BE2-4AEF-9B41-E9A409114333Q37097084-1571FF69-4B26-4DB1-9B49-B7CF7E12CE0DQ37165630-354021E5-EF7A-4375-880D-3996E574E68BQ37334904-DD56ABB0-95D5-4AE7-8565-E2C8FD8400ECQ37454802-82DCC2F8-2972-4CE3-AC17-3D9F3EB97F23Q37506839-1FFC3545-1075-4D6F-9B25-0D524E7E046D
P2860
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
@ast
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
@en
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
@nl
type
label
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
@ast
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
@en
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
@nl
prefLabel
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
@ast
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
@en
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
@nl
P2093
P2860
P1476
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women
@en
P2093
Andrew N Freedman
Barry I Graubard
Kathleen A Cronin
P2860
P304
P356
10.1158/1055-9965.EPI-09-0930
P577
2010-02-01T00:00:00Z